Clinical Observation On The Effects Of Menopausal Hormone Therapy With Different Doses On Breast Lesions

Objective:To evaluate the effects of menopausal hormone therapy(MHT)with different doses on breast lesions in perimenopausal women.Methods:A retrospective analysis of 682 cases of perimenopausal syndrome patients treated with MHT for the first time from January 2015 to December 2016 at the gynecological endocrinology clinic with long-term follow-up.117 perimenopausal women using MHT were enrolled in this study.Baseline information such as age,income,height,weight,and breast ultrasonography at the time of initial diagnosis were collected.According to the estrogen dose in the MHT regimen,117 subjects were divided into two groups,the standard dose group(group A,n = 39)and the low dose group(group B,n = 78).All breast ultrasonography data were collected after one,two and three years of medication,including the occurrence of breast hyperplasia,breast duct ectasia,breast cysts,breast nodules and the size of breast cysts and breast nodules.By comparing the difference in the incidence of breast lesions between the two groups of patients before and after the three-year follow-up,and the differences in the size of breast cysts and breast nodules,the effects of different doses of MHT on breast lesions before and after treatment wereevaluated.Results:There was no significant difference in general baseline data such as age,height,weight,body mass index(BMI),place of residence,and income between two groups before treatment(p > 0.05 for all).There was no statistically significant difference in the incidence of breast hyperplasia,duct dilatation,breast cysts,and breast nodules before and after treatment among all the subjects(p > 0.05 for all).Compared with data before treatment,there was no significant difference in the incidence of breast hyperplasia,breast duct dilatation,breast cysts,and breast nodules after one,two,and three years of treatment in both groups(p > 0.05 for all).There were also no significant differences in the incidence of breast hyperplasia and dilatation of breast ducts between two groups.(p > 0.05 for all).The incidence of breast cysts and breast nodules in group A was lower than in group B before treatment(5.1% vs 20.5%,23.1% vs 44.9%,p <0.05 for both)and there was no significant difference between two groups after one,two and three years treatment(p > 0.05 for all).There was no significant difference of time in breast cyst size among the patients with breast cyst initially in group B(p > 0.05).In group A,only 2 patients had breast cysts before treatment.One patient did not find breast cysts two years after treatment,the other patient had cysts that persisted after treatment.The BI-RADS classification of breast nodules in two groups did not exceed level 3.There was no significant difference of time and group in breast nodule size in both group(p > 0.05 for all).Conclusions:To this research object,MHT was not found increasing the risk of breast lesions in perimenopausal women for three years.There was no significant difference in the risk of breast lesions in perimenopausal women within three years between standard and low dose MHT.The safety of MHT in breast of perimenopausal women needs to be further confirmed by long-term clinical studies in large population.